1. Home
  2. XOMAO vs SPMC Comparison

XOMAO vs SPMC Comparison

Compare XOMAO & SPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XOMAO
  • SPMC
  • Stock Information
  • Founded
  • XOMAO N/A
  • SPMC 2022
  • Country
  • XOMAO United States
  • SPMC United States
  • Employees
  • XOMAO 13
  • SPMC N/A
  • Industry
  • XOMAO Biotechnology: Pharmaceutical Preparations
  • SPMC
  • Sector
  • XOMAO Health Care
  • SPMC
  • Exchange
  • XOMAO Nasdaq
  • SPMC NYSE
  • Market Cap
  • XOMAO N/A
  • SPMC N/A
  • IPO Year
  • XOMAO N/A
  • SPMC N/A
  • Fundamental
  • Price
  • XOMAO $25.25
  • SPMC $18.30
  • Analyst Decision
  • XOMAO
  • SPMC Strong Buy
  • Analyst Count
  • XOMAO 0
  • SPMC 2
  • Target Price
  • XOMAO N/A
  • SPMC $21.75
  • AVG Volume (30 Days)
  • XOMAO N/A
  • SPMC 25.9K
  • Earning Date
  • XOMAO N/A
  • SPMC 05-29-2025
  • Dividend Yield
  • XOMAO N/A
  • SPMC 15.74%
  • EPS Growth
  • XOMAO N/A
  • SPMC N/A
  • EPS
  • XOMAO N/A
  • SPMC 3.14
  • Revenue
  • XOMAO N/A
  • SPMC $46,376,428.00
  • Revenue This Year
  • XOMAO N/A
  • SPMC N/A
  • Revenue Next Year
  • XOMAO N/A
  • SPMC $51.09
  • P/E Ratio
  • XOMAO N/A
  • SPMC $5.84
  • Revenue Growth
  • XOMAO N/A
  • SPMC N/A
  • 52 Week Low
  • XOMAO N/A
  • SPMC $16.26
  • 52 Week High
  • XOMAO N/A
  • SPMC $22.30
  • Technical
  • Relative Strength Index (RSI)
  • XOMAO 52.57
  • SPMC N/A
  • Support Level
  • XOMAO $25.10
  • SPMC N/A
  • Resistance Level
  • XOMAO $25.30
  • SPMC N/A
  • Average True Range (ATR)
  • XOMAO 0.11
  • SPMC 0.00
  • MACD
  • XOMAO 0.03
  • SPMC 0.00
  • Stochastic Oscillator
  • XOMAO 71.45
  • SPMC 0.00

About XOMAO AGNC Investment Corp.

XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.

Share on Social Networks: